Journal Watch · Frontiers in Immunology · 2026
The inhibitory effect of hepatic cancer energy metabolism on immune checkpoint therapy: perspectives from single-cell multi-omics analysis.
Dual targeting of LDHA and PD-1 enhances antitumor efficacy, and the identified metabolic signature may serve as a prognostic biomarker and therapeutic target.
TL;DR
Dual targeting of LDHA and PD-1 enhances antitumor efficacy, and the identified metabolic signature may serve as a prognostic biomarker and therapeutic target.
Key findings
- The pyruvate metabolism-based signature predicted prognosis effectively.
- Combination therapy with (R)-GNE-140 and PD-1 blockade inhibited Huh7 proliferation, migration, and xenograft tumor growth without liver or renal toxicity.<h4>Conclusion</h4>ICI therapy induces metabolic remodeling in HCC, marked by pyruvate metabolism dysregulation and lactate accumulation, contributing to resistance.
- Dual targeting of LDHA and PD-1 enhances antitumor efficacy, and the identified metabolic signature may serve as a prognostic biomarker and therapeutic target.
What they did
Key transcription factors (MYC, SP5, HLF, SREBF1) were identified. CellChat revealed enhanced SPP1-CD44 and APOA1-ABCA1 signaling. Pseudotime analysis indicated terminal hepatocyte differentiation.
Full abstract (original)
Background: <h4>Objective</h4>To investigate metabolic reprogramming-especially pyruvate metabolism-in hepatocellular carcinoma (HCC) before and after immune checkpoint inhibitor (ICI) therapy, construct a metabolism-related prognostic model, and evaluate the therapeutic potential of targeting LDHA.<h4>Methods</h4>Integrated single-cell RNA-seq data (GEO, Mendeley) were analyzed using Seurat, AUCell, pySCENIC, CellChat, and Monocle. A prognostic model was developed from TCGA data by Cox and Lasso regression. Functional validation included <i>in vitro</i> CCK8 and Transwell assays in Huh7 cells and <i>in vivo</i> xenograft experiments combining the LDHA inhibitor (R)-GNE-140 with a PD-1 antibody.<h4>Results</h4>Post-ICI, HCC cells upregulated pyruvate metabolism genes (LDHA, LDHB, LDHD) but showed decreased glycolysis, lactate buildup, reduced acetylation, and suppressed TCA cycle with AMPK activation.
What they did: Key transcription factors (MYC, SP5, HLF, SREBF1) were identified. CellChat revealed enhanced SPP1-CD44 and APOA1-ABCA1 signaling. Pseudotime analysis indicated terminal hepatocyte differentiation.
Results & conclusions: The pyruvate metabolism-based signature predicted prognosis effectively. Combination therapy with (R)-GNE-140 and PD-1 blockade inhibited Huh7 proliferation, migration, and xenograft tumor growth without liver or renal toxicity.<h4>Conclusion</h4>ICI therapy induces metabolic remodeling in HCC, marked by pyruvate metabolism dysregulation and lactate accumulation, contributing to resistance. Dual targeting of LDHA and PD-1 enhances antitumor efficacy, and the identified metabolic signature may serve as a prognostic biomarker and therapeutic target.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1753670 · PubMed 42051493.
Why it matters for pharma & biotech
- Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
Dual targeting of LDHA and PD-1 enhances antitumor efficacy, and the identified metabolic signature may serve as a prognostic biomarker and therapeutic target.
What type of study is this?
It is a review / perspective, published in Frontiers in Immunology in 2026. Key transcription factors (MYC, SP5, HLF, SREBF1) were identified.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1753670. PubMed ID: 42051493. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/the-inhibitory-effect-of-hepatic-cancer-energy-metabolism-on-immune-chec-753670/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides